Objectives: Occult and subsequent pelvic serous carcinomas have been reported following RRSO
in BRCA1 and 2 mutation carriers. The frequency and clinico-pathologic features of
these tumors and recommendations regarding follow up are provided.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Gynecologic OncologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Identification
Copyright
© 2014 Published by Elsevier Inc.
